Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals(ARWR)

PASADENA, CA
Pharmaceutical1 H-1B visas (FY2023)

Focus: RNAi

Arrowhead Pharmaceuticals is a life sciences company focused on RNAi.

Gene TherapyNeurology
Funding Stage
PUBLIC
Open Jobs
4

Products & Portfolio (1)

Pipeline & Clinical Trials

Clinical Trials (1)
NCT06827288Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder
N/A
Clinical Trials (1)
NCT06796426Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS
N/A
Vitamin C
Burns
N/A
Clinical Trials (1)
NCT05612867Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vitamin C
N/A
Packed Red Blood Cell Administration
Trauma Injury
N/A
Clinical Trials (1)
NCT06402669Extremity Trauma At a Level 1 Trauma Center
N/A
No Intervention
COVID-19
N/A
Clinical Trials (1)
NCT05897528Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 Infection
N/A
No Intervention
Rectal Foreign Body
N/A
Clinical Trials (1)
NCT05888363Management and Removal of Foreign Bodies in the Emergency Department
N/A
Sofosbuvir and simeprevir
Hepatitis C
N/A
Clinical Trials (1)
NCT02485262Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience
N/A
Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Inf
Acute Kidney Injury
N/A
Clinical Trials (1)
NCT05964088Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients
N/A
Clinical Trials (1)
NCT01465516Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir
N/A
Orthopedic Surgery
Lactate Blood Increase
N/A
Clinical Trials (1)
NCT05611398Lactate Monitoring in Traumatic Long Bone Fractures Requiring Emergent Surgical Intervention
N/A
N/A
Clinical Trials (1)
NCT05400382Mindfulness to Reduce Post-cesarean Pain and Prevent Postpartum Depression
N/A
No Intervention
COVID-19
N/A
Clinical Trials (1)
NCT05859958ABO Blood Group Type Association With COVID-19 Severity
N/A
Difference in development of Acute Lung Injury in Amphetamine positive and negative patients
Burns
N/A
Clinical Trials (1)
NCT05611385Amphetamine Induced Adult Respiratory Distress Syndrome
N/A
Phase 1
Clinical Trials (1)
NCT06672445Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
Phase 1
Phase 1
Clinical Trials (1)
NCT03747224Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
Phase 1
Clinical Trials (1)
NCT04169711Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Phase 1
Phase 1
Clinical Trials (1)
NCT03783377Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
Phase 1
Azithromycin Pill
Infections
Phase 1
Clinical Trials (1)
NCT06543290Azithromycin Before Induction
Phase 1
ARO-RAGE Injection
Asthma
Phase 1
Clinical Trials (1)
NCT05533294Study of ARO-RAGE in Healthy Subjects
Phase 1
ARC-520
Healthy
Phase 1
Clinical Trials (1)
NCT02535416A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers
Phase 1
VSA001 injection
Healthy Adult Volunteers
Phase 1
Clinical Trials (1)
NCT05757596Study of VSA001 Injection in Chinese Healthy Adult Volunteers
Phase 1
ARC-520
Healthy
Phase 1
Clinical Trials (1)
NCT01872065Safety and Tolerability Study of ARC-520 in Healthy Volunteers
Phase 1
ARC-521 Injection
Hepatitis B
Phase 1
Clinical Trials (1)
NCT02797522A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
Phase 1
Phase 1
Clinical Trials (1)
NCT02363946A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Phase 1
Phase 1
Clinical Trials (1)
NCT05949294Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
Phase 1
Phase 1
Clinical Trials (1)
NCT03362242Study of ARO-AAT in Normal Adult Volunteers
Phase 1
Phase 1/2
Clinical Trials (1)
NCT06209177Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT04202354Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH
Phase 1/2
ARO-RAGE
Asthma
Phase 1/2
Clinical Trials (1)
NCT05276570Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease
Phase 1/2
ARO-INHBE
Obesity
Phase 1/2
Clinical Trials (1)
NCT06700538Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus
Phase 1/2
ARO-MUC5AC
Asthma
Phase 1/2
Clinical Trials (1)
NCT05292950Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
Phase 1/2
Clinical Trials (1)
NCT04375514Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT03365947Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT07223658Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
Phase 1/2
ARO-MMP7 Inhalation Solution
Idiopathic Pulmonary Fibrosis
Phase 1/2
Clinical Trials (1)
NCT05537025Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT07221344Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
Phase 1/2
ARO-DM1 Intravenous
Myotonic Dystrophy 1
Phase 1/2
Clinical Trials (1)
NCT06138743Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
Phase 1/2
ARO-DUX4 for Injection
Facio-Scapulo-Humeral Dystrophy
Phase 1/2
Clinical Trials (1)
NCT06131983Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT05083364Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
Phase 1/2
ARO-ALK7
Obesity
Phase 1/2
Clinical Trials (1)
NCT06937203Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus
Phase 1/2
ARC-520 Injection
Hepatitis B
Phase 2
Clinical Trials (1)
NCT02738008Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
Phase 2
Clinical Trials (1)
NCT03946449Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
Phase 2
ARC-520 Injection
Chronic Hepatitis B
Phase 2
Clinical Trials (1)
NCT02349126Study of ARC-520 in Patient With Chronic Hepatitis B Virus
Phase 2
ARO-APOC3
Dyslipidemias
Phase 2
Clinical Trials (1)
NCT05413135Study of ARO-APOC3 in Adults With Dyslipidemia
Phase 2
Phase 2
Clinical Trials (1)
NCT02452528Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
Phase 2
Phase 2
Clinical Trials (1)
NCT02900183Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
Phase 2
Phase 2
Clinical Trials (1)
NCT02577029Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Phase 2
ARO-RAGE
Asthma
Phase 2
Clinical Trials (1)
NCT07241546Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
Phase 2
Phase 2
Clinical Trials (1)
NCT02065336A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Phase 2
Phase 2
Clinical Trials (1)
NCT03945292Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
Phase 2

Open Jobs (4)

Interview Prep Quick Facts
Portfolio: 1 approved product, 70 clinical trials
Top TAs: Rare Diseases
H-1B (2023): 1 approval
SEC Filings: 2 available
Open Roles: 4 active jobs
Portfolio Health
Launch1 (100%)
1 total products
Therapeutic Area Focus
Rare Diseases
1 marketed
Marketed
Pipeline

Financials (FY2025)

Revenue
$241M1%
R&D Spend
$353M(147%)19%
Net Income
-$205M

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub